Morgan Stanley’s Mateon Therapeutics, Inc. MATN Stock Holding History

Morgan Stanley’s Portfolio MATN Stock Details MATN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,000	Closed	-$1K	–	6650
2016 Q3	$1K	Hold	1,000	–	–	﹤0.01%	6476
2016 Q2	$1K	Buy	+1,000	New	+$708	﹤0.01%	6474

Other funds holding MATN

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Morgan Stanley's MATN Position: Q4 2016 in Review

Morgan Stanley sold out of Mateon Therapeutics, Inc. (MATN) in Q4 2016, closing a stake of 1,000 shares — an estimated $1K sold.

Morgan Stanley first reported a position in MATN in Q2 2016 and held it in 2 quarters. The position peaked at $1K in Q3 2016. 1 fund tracked by Wall St. Rank holds MATN as of Q4 2016.

Morgan Stanley reported no remaining Mateon Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
Morgan Stanley sold 1,000 Mateon Therapeutics, Inc. shares in Q4 2016, an estimated $1K.
Morgan Stanley first reported a position in Mateon Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
Morgan Stanley's Mateon Therapeutics, Inc. position peaked at $1K in Q3 2016.
1 fund tracked by Wall St. Rank held Mateon Therapeutics, Inc. as of Q4 2016.

Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.